Evocalcet

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.^[1] It acts as a calcium-sensing receptor agonist.^[2]

Trade namesOrkedia

ATC code

• H05BX06 (WHO)

CAS Number

• 870964-67-3

PubChem CID

• 71242808

Quick facts Clinical data, Trade names ...

Evocalcet

Clinical data
Trade names	Orkedia
ATC code	H05BX06 (WHO)
Identifiers
IUPAC name 2-[4-[(3S)-3-[[(1R)-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid
CAS Number	870964-67-3
PubChem CID	71242808
DrugBank	DB12388
ChemSpider	44208828
UNII	E58MLH082P
KEGG	D11063
ChEMBL	ChEMBL4297621
CompTox Dashboard (EPA)	DTXSID101132784
Chemical and physical data
Formula	C24H26N2O2
Molar mass	374.484 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](C1=CC=CC2=CC=CC=C21)N[C@H]3CCN(C3)C4=CC=C(C=C4)CC(=O)O
InChI InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1 Key:RZNUIYPHQFXBAN-XLIONFOSSA-N

Close

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.^[3]